MedicaidPrior AuthMedium impact
Asparlas™ (calaspargase pegol-mknl) (New)
Humana·LA · Oncology, Hematology, Pediatrics·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Asparlas (calaspargase pegol-mknl), a chemotherapy drug used to treat acute lymphoblastic leukemia in patients 21 years and younger. The policy requires prior authorization with specific approval criteria including diagnosis confirmation, use as part of multi-agent chemotherapy, and age restrictions.
Action Required
Before December 1, 2025: Billing team must update prior authorization workflow to obtain approval for Asparlas (calaspargase pegol-mknl) for Louisiana Medicaid patients. Providers must document ALL diagnosis, age 21 or younger, use as part of multi-agent chemotherapy regimen, and verify patient has no exclusion criteria before prescribing. Claims will be denied without prior authorization.